EE04961B1 - N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis - Google Patents

N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Info

Publication number
EE04961B1
EE04961B1 EEP200100447A EEP200100447A EE04961B1 EE 04961 B1 EE04961 B1 EE 04961B1 EE P200100447 A EEP200100447 A EE P200100447A EE P200100447 A EEP200100447 A EE P200100447A EE 04961 B1 EE04961 B1 EE 04961B1
Authority
EE
Estonia
Prior art keywords
insulin resistance
propoxy
pyridine
oxide
methods
Prior art date
Application number
EEP200100447A
Other languages
English (en)
Estonian (et)
Inventor
βria K�rthy M
B�r� Katalin
βroly Nagy K
βszl� �r�gdi L
Cs βkai Zita
Szilbereky Jen�
βs Mogyor�si Tam
T�r�k Magdolna
βs Kom βromi Andr
M βrv βnyos Ede
βly Barab βs Mih
βlyn� Kardos Mih
βn Nagy Zolt
βszl� Kor βnyi L
Nagy Melinda
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200100447A publication Critical patent/EE200100447A/xx
Publication of EE04961B1 publication Critical patent/EE04961B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100447A 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis EE04961B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
EE200100447A EE200100447A (et) 2002-12-16
EE04961B1 true EE04961B1 (et) 2008-02-15

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100447A EE04961B1 (et) 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Country Status (27)

Country Link
US (1) US6649628B1 (ja)
EP (1) EP1163224B1 (ja)
JP (1) JP4689838B2 (ja)
KR (1) KR100676124B1 (ja)
AT (1) ATE237590T1 (ja)
AU (1) AU779096B2 (ja)
BG (1) BG65178B1 (ja)
BR (1) BR0008969A (ja)
CA (1) CA2360451C (ja)
CZ (1) CZ297386B6 (ja)
DE (1) DE60002187T2 (ja)
DK (1) DK1163224T3 (ja)
EE (1) EE04961B1 (ja)
ES (1) ES2193055T3 (ja)
HR (1) HRP20010584B1 (ja)
HU (1) HUP9900475D0 (ja)
IL (2) IL144866A0 (ja)
NO (1) NO319793B1 (ja)
PL (1) PL197692B1 (ja)
PT (1) PT1163224E (ja)
RS (1) RS50083B (ja)
RU (1) RU2250901C2 (ja)
SI (1) SI1163224T1 (ja)
SK (1) SK287063B6 (ja)
UA (1) UA72495C2 (ja)
WO (1) WO2000050403A1 (ja)
ZA (1) ZA200106488B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
PL371251A1 (en) * 2002-01-11 2005-06-13 Biorex Kutato Es Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
BRPI0919867A2 (pt) * 2008-11-18 2015-12-15 Santen Pharmaceutical Co Ltd agente terapeutico ou profilatico para uma doenca degenerativa coriorretiniana, e metodo profilatico ou terapeutico para uma doenca degenerativa coriorrentiniana
PL2646044T3 (pl) 2010-11-30 2020-03-31 Orphazyme A/S Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
ES2691981T3 (es) * 2012-09-06 2018-11-29 Mcpharma Biotech Inc. Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata
CA2884777C (en) 2012-09-14 2018-02-27 Saint-Gobain Glass France Pane with an electrical connection element
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
EP3922242A1 (en) * 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3782624A1 (en) * 2016-04-29 2021-02-24 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
BR112020024182A2 (pt) 2018-05-28 2021-03-30 Orphazyme A/S Métodos para detectar proteína de choque térmico 70, para diagnosticar uma doença apresentando um nível reduzido de proteína de choque térmico 70, para selecionar um paciente tendo uma doença apresentando um nível reduzido de hsp70, para monitorar progressão de doença em um indivíduo, para monitorar a eficácia de uma terapia para tratamento de uma doença, e, para ajustar a dosagem de um derivado de hidroxilamina de molécula pequena.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
CN116075305A (zh) 2020-06-24 2023-05-05 柯姆药物丹麦股份公司 用于治疗戈谢病的阿瑞洛莫
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US20240115558A1 (en) 2020-12-24 2024-04-11 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
BR0008969A (pt) 2001-11-27
IL144866A0 (en) 2002-06-30
HRP20010584B1 (en) 2010-08-31
NO319793B1 (no) 2005-09-12
RU2250901C2 (ru) 2005-04-27
SK287063B6 (sk) 2009-10-07
RS50083B (sr) 2009-01-22
CZ20013053A3 (cs) 2002-01-16
PL350915A1 (en) 2003-02-10
HUP9900475D0 (en) 1999-04-28
CA2360451A1 (en) 2000-08-31
ATE237590T1 (de) 2003-05-15
CA2360451C (en) 2011-01-04
YU60301A (sh) 2004-05-12
PL197692B1 (pl) 2008-04-30
WO2000050403A1 (en) 2000-08-31
DE60002187T2 (de) 2003-12-11
SK11582001A3 (sk) 2001-12-03
IL144866A (en) 2007-07-04
EP1163224A1 (en) 2001-12-19
HRP20010584A2 (en) 2002-08-31
PT1163224E (pt) 2003-07-31
DE60002187D1 (de) 2003-05-22
SI1163224T1 (en) 2003-08-31
BG105837A (en) 2002-03-29
JP2002537384A (ja) 2002-11-05
UA72495C2 (uk) 2005-03-15
KR20010102410A (ko) 2001-11-15
ES2193055T3 (es) 2003-11-01
DK1163224T3 (da) 2003-08-04
AU779096B2 (en) 2005-01-06
JP4689838B2 (ja) 2011-05-25
EE200100447A (et) 2002-12-16
KR100676124B1 (ko) 2007-01-31
EP1163224B1 (en) 2003-04-16
CZ297386B6 (cs) 2006-11-15
US6649628B1 (en) 2003-11-18
AU3182400A (en) 2000-09-14
BG65178B1 (bg) 2007-05-31
NO20014103L (no) 2001-10-22
ZA200106488B (en) 2002-08-07
NO20014103D0 (no) 2001-08-23

Similar Documents

Publication Publication Date Title
EE04961B1 (et) N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
TW229205B (ja)
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EE200400032A (et) Polüfenooliühendit sisaldav farmatseutiline toitekompositsioon ning selle kasutamine vähktõve ravimiseks
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
SE0002934D0 (sv) New aporphine esters and in their use in therapy
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
GEP20094651B (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DK1232173T3 (da) Nye fusidinsyrederivater
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas
SE0202608D0 (sv) New sequences
DE60224078D1 (de) Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
MXPA05014081A (es) Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas.
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110224